Core Insights - 60 Degrees Pharmaceuticals, Inc. announced a study revealing that 24% of 50 patients with chronic fatigue were infected with Babesia, a parasite linked to babesiosis, suggesting a potential connection between Babesia infection and prolonged recovery times in chronic fatigue patients [1][2][9] Group 1: Study Findings - The study conducted by North Carolina State University involved 50 participants who reported chronic diseases and potential exposure to arthropod vectors, with all participants experiencing fatigue for at least six months [5] - The findings support the hypothesis that Babesia infection may be associated with chronic diseases, particularly in prolonging recovery times for patients suffering from chronic fatigue [2][4] Group 2: Ongoing Research - The B-Free Chronic Babesiosis Study is currently evaluating the efficacy and safety of the ARAKODA regimen (tafenoquine) over 90 days for resolving severe fatigue in chronic babesiosis patients, with enrollment taking place at the Icahn School of Medicine at Mount Sinai in New York [3][9] - The study's results highlight the need for further prospective controlled studies to better understand the relationship between Babesia infection and chronic diseases [4] Group 3: Babesiosis Overview - Babesiosis is a tick-borne illness caused by Babesia parasites, leading to symptoms such as fevers, chills, and fatigue, with severe cases posing life-threatening risks, especially to the elderly and immunosuppressed [7] - The incidence of babesiosis is rapidly increasing, particularly in the Northeast, with an estimated minimum annual incidence of at least 25,000 cases in the U.S., although the actual number may be significantly higher [7][8] Group 4: Company Background - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA (tafenoquine), for malaria prevention in 2018 [10] - The company collaborates with prominent research and academic organizations in the U.S. and Australia, and is headquartered in Washington, D.C. [10]